11,889 Shares in Enovis Corporation (NYSE:ENOV) Acquired by First National Advisers LLC

First National Advisers LLC purchased a new position in Enovis Corporation (NYSE:ENOV) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,889 shares of the company’s stock, valued at approximately $454,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Quadrant Capital Group LLC increased its holdings in Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock worth $30,000 after buying an additional 239 shares during the period. California State Teachers Retirement System increased its holdings in Enovis by 0.7% in the 4th quarter. California State Teachers Retirement System now owns 52,236 shares of the company’s stock worth $2,292,000 after buying an additional 350 shares during the period. Farther Finance Advisors LLC increased its holdings in Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after buying an additional 536 shares during the period. Treasurer of the State of North Carolina grew its stake in shares of Enovis by 2.5% during the 4th quarter. Treasurer of the State of North Carolina now owns 24,347 shares of the company’s stock worth $1,068,000 after purchasing an additional 590 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Enovis during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ENOV. Needham & Company LLC dropped their price objective on shares of Enovis from $64.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Evercore ISI dropped their price objective on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Canaccord Genuity Group dropped their price objective on shares of Enovis from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, JMP Securities dropped their price objective on shares of Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $55.60.

Enovis Trading Up 1.4%

Shares of NYSE:ENOV opened at $27.53 on Monday. Enovis Corporation has a 1 year low of $25.93 and a 1 year high of $49.83. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -1.97 and a beta of 1.70. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.55 and a quick ratio of 1.32. The business’s 50 day moving average price is $31.69 and its 200-day moving average price is $36.49.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The firm had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. During the same quarter last year, the firm posted $0.50 EPS. The business’s revenue was up 8.2% on a year-over-year basis. On average, equities research analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.